Tag Archives: ACRS

Hot Growth Stocks To Buy For 2019

Wall Street is enamored with the rare-disease drugmaker Sarepta Therapeutics (NASDAQ:SRPT). Despite this stock’s 166% surge this year, after all, analysts have been quick to upgrade the biotech’s shares following a positive, albeit extremely preliminary, peak at the company’s experimental gene therapy for Duchenne muscular dystrophy (DMD) on Tuesday.  

H.C. Wainwright analyst Debjit Chattopadhyay, for example, raised his 12-month price target on the stock to a jaw-dropping $267. That overtly bullish forecast implies an upside potential of more than 85% from here. 

Image Source: Getty Images.

Is Wall Street’s faith in Sarepta well founded? Let’s dig deeper to find out. 

Orphan drugmakers are worth a premium

One of the main reasons Wall Street can’t get enough of Sarepta is because of the rising tide across the rare-disease drug market at the moment. A recent industry report by EvaluateGroup, for instance, has the orphan drug space — or drugs intended for fairly small patient populations like DMD — nearly doubling in size over the course of 2018 to 2024. As the market share leader in treatments for DMD, Sarepta is therefore primed to benefit from this period of hypergrowth.

Hot Growth Stocks To Buy For 2019: Natural Gas(NG)

Advisors’ Opinion:

  • [By Logan Wallace]

    NovaGold Resources Inc. (TSE:NG) (AMEX:NG) insider David Ottewell sold 60,309 shares of the business’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of C$4.85, for a total value of C$292,498.65.

  • [By Shane Hupp]

    JPMorgan Chase set a GBX 870 ($11.80) target price on National Grid (LON:NG) in a research note released on Monday. The brokerage currently has a buy rating on the stock.

  • [By Money Morning News Team]

    Canadian gold mining company NovaGold Resources Inc. (NYSE: NG) shows an even starker change in sentiment. In the last six months, the volume of short bets on the stock declined 32.75%, from 19.05 million shares to 12.81 million.

Hot Growth Stocks To Buy For 2019: New Relic, Inc.(NEWR)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer, Keith Speights, and Brian Stoffel]

    That’s certainly the case with surprisingly diversified biotech company Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), out-of-favor outlet mall owner Tanger Factory Outlet Centers, Inc. (NYSE:SKT), and expanding software-maker New Relic, Inc. (NYSE:NEWR). Take the time for a deep dive, and you might find that one of these three mid-cap stocks is just right for your portfolio today.

  • [By Ethan Ryder]

    UBS Group AG lifted its stake in shares of New Relic Inc (NYSE:NEWR) by 120.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,623 shares of the software maker’s stock after buying an additional 16,190 shares during the quarter. UBS Group AG owned 0.05% of New Relic worth $2,195,000 as of its most recent filing with the SEC.

  • [By Motley Fool Transcribing]

    New Relic (NYSE:NEWR) Q3 2019 Earnings Conference CallFeb. 6, 2019 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    New Relic (NYSE:NEWR) had its target price increased by BMO Capital Markets from $95.00 to $110.00 in a report published on Tuesday, Marketbeat reports. BMO Capital Markets currently has an outperform rating on the software maker’s stock.

Hot Growth Stocks To Buy For 2019: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Cadence Capital Management LLC grew its stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 12.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 33,286 shares of the biotechnology company’s stock after buying an additional 3,593 shares during the quarter. Cadence Capital Management LLC owned 0.11% of Aclaris Therapeutics worth $665,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

  • [By Stephan Byrd]

    Headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.9638334424702 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Shane Hupp]

    Aclaris Therapeutics Inc (NASDAQ:ACRS) Director Stephen A. Tullman bought 6,600 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, August 23rd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the acquisition, the director now owns 170,357 shares of the company’s stock, valued at $2,555,355. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Logan Wallace]

    News headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.0807215270757 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

best stock buys

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-101880049&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/101880049/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; FABRICE COFFRINI/AFP/Getty Images

Companies keep churning out impressive earnings, but the market doesn&a;rsquo;t seem to give them much credit. Instead, fear and caution remain the watchwords as the Dow Jones Industrial Average enters Wednesday on a five-session losing streak.

&l;strong&g;Morning Earnings Wrap&l;/strong&g;

Boeing became the latest member of the D&l;span&g;ow Jones Industrial Average&a;nbsp;&l;/span&g;30 to smash Wall Street analysts&a;rsquo; projections early Wednesday, firing up earnings per share of $3.64 vs. analysts&a;rsquo; consensus of $2.56. Revenue of $23.38 billion was more than $1 billion ahead of the $22.2 billion analysts had expected, and the company also raised its outlook. Strength in the commercial air division helped Boeing project a healthy sales picture.

best stock buys: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

  • [By Logan Wallace]

    Aclaris Therapeutics (NASDAQ:ACRS) has received a consensus recommendation of “Hold” from the eight research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $46.00.

  • [By Chris Lange]

    Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.

best stock buys: Primerica, Inc.(PRI)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    Marriott International, Inc. (NASDAQ: MAR) is projected to post quarterly earnings at $1.22 per share on revenue of $5.72 billion.
    Electronic Arts Inc. (NASDAQ: EA) is estimated to post quarterly earnings at $1.04 per share on revenue of $5.68 billion.
    The Walt Disney Company (NYSE: DIS) is projected to post quarterly earnings at $1.68 per share on revenue of $14.05 billion.
    Papa John's International, Inc. (NASDAQ: PZZA) is expected to post quarterly earnings at $0.62 per share on revenue of $441.73 million.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post quarterly earnings at $2.77 per share on revenue of $434.87 million.
    Sun Life Financial Inc. (NYSE: SLF) is estimated to post quarterly earnings at $0.89 per share on revenue of $6.38 billion.
    LATAM Airlines Group S.A. (NYSE: LTM) is expected to post quarterly earnings at $0.16 per share on revenue of $2.70 billion.
    Liberty Global plc (NASDAQ: LBTYA) is projected to post quarterly earnings at $0.02 per share on revenue of $4.05 billion.
    TripAdvisor, Inc. (NASDAQ: TRIP) is expected to post quarterly earnings at $0.16 per share on revenue of $362.11 million.
    The Wendy's Company (NASDAQ: WEN) is projected to post quarterly earnings at $0.1 per share on revenue of $379.98 million.
    A-Mark Precious Metals, Inc. (NASDAQ: AMRK) is expected to post quarterly earnings at $0.06 per share on revenue of $1.69 billion.
    Monster Beverage Corporation (NASDAQ: MNST) is estimated to post quarterly earnings at $0.4 per share on revenue of $849.38 million.
    Convergys Corporation (NYSE: CVG) is expected to post quarterly earnings at $0.4 per share on revenue of $670.10 million.
    ScanSource, Inc. (NASDAQ: SCSC) is projected to post quarterly earnings at $0.7 per share on revenue of $875.91 million.
    KAR Auction Services, Inc. (NYSE: KAR) is expected to post quarterly earnings at $0.76 per share on revenue of $923.13

  • [By Joseph Griffin]

    Primerica (NYSE:PRI) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $103.00.

best stock buys: RELM Wireless Corporation(RWC)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shorting small cap wireless communications manufacturer RELM Wireless Corporation (NYSEMKT: RWC):

best stock buys: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Peter Graham]

    Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:

  • [By Paul Ausick]

    Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.

best stock buys: DXP Enterprises Inc.(DXPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of DXP Enterprises Inc (NASDAQ: DXPE) got a boost, shooting up 22 percent to $40.27 after the company posted upbeat quarterly results.

    Nature's Sunshine Prod. (NASDAQ: NATR) shares were also up, gaining 28 percent to $11.35 as the company disclosed that it has received its direct selling license in China.

  • [By Lisa Levin]

    Shares of DXP Enterprises Inc (NASDAQ: DXPE) were down 17 percent to $24.00. DXP Enterprises reported preliminary revenue of $228 million to $231 million for the third quarter.

best stock buys: Advanced Semiconductor Engineering, Inc.(ASX)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, technology shares rose by just 0.2 percent. Meanwhile, top losers in the sector included Advanced Semiconductor Engnrng Inc (ADR) (NYSE: ASX), down 6 percent, and Bitauto Hldg Ltd (ADR) (NYSE: BITA) down 6 percent.

  • [By Lisa Levin]

    In trading on Tuesday, technology shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Advanced Semiconductor Engnrng Inc (ADR) (NYSE: ASX), down 6 percent, and QAD Inc. (NASDAQ: QADB) down 5 percent.

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

    Read more of Cramer’s comments about the stocks in the Lightning Round.

  • [By Peter Graham]

    A look at the long term performance of small cap Amkor Technology along with Taiwan based peers like large cap mid cap Siliconware Precision Industries (NASDAQ: SPIL) and Advanced Semiconductor Engineering (NYSE: ASX) show considerable volatility:

Top Insurance Stocks To Buy Right Now

Distributions Out of a Cash Value Life Insurance Policy

AXA Plans to Sell Part of U.S. Life Unit to Public

You Could Be a Federal Long-Term Care Policy Advisor

Edward Bonach, the chief executive officer of CNO Financial Group Inc., plans to retire from the CEO post at the end of the year, the company announced today.

Gary Bhojwani, the Carmel, Indiana-based company’s president, will succeed Bonach as CEO at the end of  the year, the company said.

Edward Bonach (Photo: CNO)

Allianz launched on Monday a series of animated videos for consumers that address annuity information and misconceptions.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources Help Small Business Owners Save BIG on Their Taxes

Gain access to powerful tax planning strategies that CPAs aren’t offering

Top Insurance Stocks To Buy Right Now: H&R Block, Inc.(HRB)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer also called out H&R Block (HRB) , a company even he was skeptical of, but also one that rose — up 14.8% on strong earnings.

    With the Federal Reserve eyeing four possible rate hikes, Cramer said is not the time to give up on the banks, which is why he owns Citigroup (C) for Action Alerts PLUS. Cramer said he wouldn’t give up on Dow Chemical (DOW) , Arconic (ARNC) or the oil stocks either, as oil will be resuming its climb after this brief pause. He recommended EOG Resources (EOG) as a favorite in that group.

  • [By Chris Lange]

    H&R Block Inc. (NYSE: HRB) is set to release its most recent quarterly results Wednesday. The consensus forecast is a net loss of $0.72 per share and revenue of $131.67 million. Shares were most recently traded at $25.86. The consensus price target is $23.92, and the 52-week range is $19.85 to $31.80.

  • [By Dan Caplinger]

    Even with the volatility, some stocks shined, and H&R Block (NYSE:HRB), PPG Industries (NYSE:PPG), and Global Blood Therapeutics (NASDAQ:GBT) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

Top Insurance Stocks To Buy Right Now: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

  • [By Chris Lange]

    Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.

Top Insurance Stocks To Buy Right Now: Headwaters Incorporated(HW)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Building products provider Headwaters (HW) said Sunday that it has agreed to be acquired by Australian construction materials supplier Boral for $24.25 per share, or $2.6 billion, in cash.

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Headwaters (HW) , EnergySolutions (ES) , Western Refining (WNR) and Horizon Pharmaceuticals (HZNP) .

    No-Huddle Offense

Top 10 Blue Chip Stocks To Invest In 2019

It was a mixed day for stocks as blue chips managed to squeak out a gain and small-caps got crushed ahead of tomorrow’s Fed announcement.

Keith Bedford for The Wall Street Journal

The S&P 500 fell 0.2% to 2,015.93 today, while the Dow Jones Industrial Average rose 22.40 points, or 0.1%, to 17,251.53. The Nasdaq Composite fell 0.5% to 4,728.67. The Russell 2000 tumbled 1.6% to 1,066.67, the first time since Sept. 2011 that the small-company benchmark fell by at least 1.5% and the Dow Jones Industrial Average finished higher.

The folks at Bespoke Investment Group consider the Russell 2000′s underperformance versus the S&P 500 this year:

Including today, the S&P 500 is down 1.6%, while the Russell 2000 is down 6.1%. Todays underperformance in small caps is just a continuation of what has been an extremely consistent trend of daily underperformance this year.

Top 10 Blue Chip Stocks To Invest In 2019: Crestwood Equity Partners LP(CEQP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Crestwood Equity Partners LP (NYSE: CEQP) shares shot up 45 percent to $18.54 following the announcement of a new joint venture with Consolidated Edison, Inc. (NYSE: ED). Subsidiaries of both companies entered into an agreement on Thursday to form a joint venture in which they will jointly own and develop Crestwood’s existing natural gas pipeline and storage business in norther Pennsylvania and southern New York.

Top 10 Blue Chip Stocks To Invest In 2019: JAKKS Pacific, Inc.(JAKK)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One under-$10 toy player that’s trending very close to triggering a major breakout trade is Jakks Pacific (JAKK), which is a producer and marketer of children’s toys and other consumer products. This stock has been destroyed by the bears so far in 2013, with shares off sharply by 60%.

    If you take a look at the chart for Jakks Pacific, you’ll notice that this stock has been downtrending badly for the last two months and change, with shares plunging from its high of $11.75 to its recent low of $4.82 a share. During that downtrend, shares of JAKK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of JAKK look like they might be ready to see an end to its downside volatility in the short-term if the recent lows can hold. I believe this due to the fact that JAKK has started to move sideways and trend within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in JAKK if it manages to break out above some near-term overhead resistance levels at $5.08 to $5.27 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 695,817 shares. If that breakout triggers soon, then JAKK will set up to re-test or possibly take out its next major overhead resistance levels at $5.68 to its 50-day moving average at $6.07 a share. Any high-volume move above its 50-day will then put $7 to $8 into range for shares of JAKK.

    Traders can look to buy JAKK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.87 to $4.82 a share. One can also buy JAKK off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Peter Graham]

    A long term performance chart shows shares of Hasbro, Inc largely trending upward while shares of peers like mid cap Mattel, Inc (NASDAQ: MAT) and small cap JAKKS Pacific, Inc (NASDAQ: JAKK) have largely trended downward:

  • [By Peter Graham]

    A long term performance chart shows shares of Hasbro, Inc largely going in one direction while shares of peers likemid cap Mattel, Inc (NASDAQ: MAT)and small cap JAKKS Pacific, Inc (NASDAQ: JAKK) have gone in the other direction:

Top 10 Blue Chip Stocks To Invest In 2019: Popular, Inc.(BPOP)

Advisors’ Opinion:

  • [By Peter Graham]

    Founded in 1893, mid cap Popular Inc (NASDAQ: BPOP) is the leading banking institution by both assets and deposits in Puerto Rico and ranks among the top 50 U.S. banks by assets. Popular provides retail, mortgage and commercial banking services through its principal banking subsidiary, Banco Popular de Puerto Rico, as well as auto and equipment leasing and financing, investment banking, broker-dealer and insurance services through specialized subsidiaries. In the United States, Popular has established a community-banking franchise providing a broad range of financial services and products with branches in New York, New Jersey and Florida under the name of Popular Community Bank.

  • [By Ben Levisohn]

    We believe investors should continue to own three types of bank stocks: “Return of Capital (RC) Stocks”, “Risk On (RO) Stocks”, and “Multiple Revaluation (MR) Stocks.” RC stocks include M&T Bank (MTB), PNC Financial Services Group (PNC), and SunTrust Banks (STI); RO stocks include Bank of America, Popular (BPOP), Citigroup, JPMorgan, and KeyCorp (KEY); and MR stocks include BB&T (BBT) and PNC Financial Services Group (PNC).

Top 10 Blue Chip Stocks To Invest In 2019: Express-1 Expedited Solutions Inc.(XPO)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    With a trailing 12-month price-to-earnings ratio of 28.79, FedEx’s valuation is in line with UPS (27.52) and far cheaper than XPO Logistics (XPO) (90.25).

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on GlaxoSmithKline (GSK) , Chubb (CB) , XPO Logistics (XPO) , FedEx (FDX) and Nordson (NDSN) .

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

Top 10 Blue Chip Stocks To Invest In 2019: Vanguard Mega Cap Value ETF (MGV)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).

Top 10 Blue Chip Stocks To Invest In 2019: Starbucks Corporation(SBUX)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Believe it or not, Howard Schultz has tried to leave Starbucks Corporation (NASDAQ: SBUX) before. This time looks like it will be for real. Starbucks announced on Thursday that Howard Schultz is departing the day-to-day operations as CEO of the company.

  • [By WWW.USATODAY.COM]

    That’s what happens when someone decides to give a gift card. It counts as a gift, but in most cases a Starbucks (NASDAQ: SBUX) card (which one in six Americans received in 2015) or any other gift card mostly says either “I don’t know you that well” or “I don’t care about you that much.”

  • [By Jack Delaney]

    And because this California cannabis company plans to become the “Starbucks Corp. (Nasdaq: SBUX) of weed,” we had to make sure you knew about it now before January 2018.

Top 10 Blue Chip Stocks To Invest In 2019: Randgold Resources Limited(GOLD)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Gold mining stocks were also lower, with Randgold Resources (GOLD) falling around 1.5% and Fresnillo Plc (FNLPF) slipping 0.85%. Randgold’s 10.66% advance over the past three months, however, has nearly doubled that of spot gold prices while Fresnillo’s 15.82% rise is nearly three times higher than the bullion’s gain over the same period. 

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

  • [By Alex McGuire]

    This list shows the top-performing gold stocks this month, which we’ll be watching in September 2017. While these stocks posted gains in August, we still aren’t recommending them. Instead, we’re going to show you Money Morning Resource Specialist Peter Krauth’s pick for the best gold stock to buy this year…

    Top Gold Stock Share Price August 2017 Gain
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $6.35 +22.9%
    Iamgold Corp. (NYSE: IAG) $6.49 +20%
    Alamos Gold Inc. (NYSE: AGI) $8.17 +15.1%
    Franco Nevada Corp. (NYSE: FNV) $81.20 +11.6%
    Hudbay Minerals Inc. (NYSE: HBM) $8.70 +11.5%
    Gold Fields Ltd. (NYSE ADR: GFI) $4.42 +10.9%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $101.90 +9.6%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.97 +8.8%
    Agnico Eagle Mines Ltd. (NYSE: AEM) $50.60 +8.4%
    Yamana Gold Inc. (NYSE: AUY) $2.81 +7.9%

    Life-Changing Profits: This investing strategy has racked up 30 triple-digit wins so far this year – and 46 in the last 12 months. To learn how to get in position for the next one, click here now…

  • [By SEEKINGALPHA.COM]

    Thus we are still extremely cautious in gold as we are a bit worried about next week’s job report being positive and knocking gold down, but we maintain our core positions in gold. But we aren’t looking to re-establish any of our sold gold and silver positions just yet until we see more of a pullback in the metals or a bad jobs report and thus we think investors should hold off or lighten up on gold positions in the ETF’s and miners such as the SPDR Gold Trust ETF (NYSEARCA:GLD), ETFS Physical Swiss Gold Trust ETF (NYSEARCA:SGOL), iShares Silver Trust (NYSEARCA:SLV), and miners such as Randgold (GOLD) and Barrick Gold (NYSE:ABX).

  • [By WWW.THESTREET.COM]

    Seabridge Gold (SA) : “I like profitable gold companies like Randgold Resources (GOLD) and Kirkland Lake (KL) .”

    Impinj (PI) : “That’s a crowded market, you need to be careful.”

Top 10 Blue Chip Stocks To Invest In 2019: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

  • [By Chris Lange]

    Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.

Top 10 Blue Chip Stocks To Invest In 2019: Methanex Corporation(MEOH)

Advisors’ Opinion:

  • [By Jim Robertson]

    Back in February of last year, we suggested Methanex Corporation (MEOH), which ended up providing us with some pretty good gains in a fairly short amount of time, and based on what’s happening with the stock technically right now, it could be another gainer over the next several days to few weeks.

Top 10 Blue Chip Stocks To Invest In 2019: BAE Systems PLC (BAESY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    BAE Systems (BAESY) and other defense stocks gained on Friday morning after President Donald Trump’s strike on Syria prompted investors to consider the possibility of greater Western involvement in the Syrian conflict.

  • [By SEEKINGALPHA.COM]

    Rheinmetall is currently trading at 15.7x forward earnings and 2.5x book value, a valuation that is closer to its automotive suppliers peers. Compared to its defense peers, its valuation is clearly cheap, as shown in the next table. This shows that Rheinmetall is usually benchmarked against its auto peers, even though 53% of its sales and 41% of operating income have come from its defense unit in the past year.

    P/E P/BV Rheinmetall 15.7 2.5 Continental AG 12.4 2.9 Valeo 13.1 3.6 Brembo (OTC:BRBOF) 17.0 5.2 Leoni (OTC:LNNNY) 13.2 1.9 Auto Peers Average 14.3 3.2 Airbus 24.0 6.8 Leonardo 16.8 2.0 BAE Systems (OTCPK:BAESY) 18.5 5.7 Thales (OTCPK:THLEY) 22.4 4.3 Defense Sector Average 19.2 4.4

    Source: Bloomberg